ICER Weighs in on Rebates – Again Misses the Mark by an Ocean

ICER Weighs in on Rebates – Again Misses the Mark by an Ocean

The Institute for Clinical and Economic Review (ICER) posted a white paper[i]that attempts to provide insights into how rebates on prescription drugs is increasing costs for patients and then offers some solutions. However, this paper takes the perspective that the...

Unsupported Price Increase Assessments 2019

Patients Rising Now advocates on behalf of patients with life-threatening conditions and chronic diseases for them to have access to vital therapies and services. Access is a matter of survival for those patients, and it spans affordability, insurance coverage, and...

Baker’s Orwellian Drug Pricing Policy

THE BAKER ADMINISTRATION recently released its budget proposal for one of their most high-profile issues: drug prices in the Medicaid program. To the surprise of many in the biopharmaceutical industry, there are some promising initiatives in the proposal from an...